734 related articles for article (PubMed ID: 10599717)
21. High sensitive thyroglobulin assay on thyroxine therapy: can it avoid stimulation test in low and high risk differentiated thyroid carcinoma patients?
Trimboli P; La Torre D; Ceriani L; Condorelli E; Laurenti O; Romanelli F; Ventura C; Signore A; Valabrega S; Giovanella L
Horm Metab Res; 2013 Sep; 45(9):664-8. PubMed ID: 23720229
[TBL] [Abstract][Full Text] [Related]
22. Thyroglobulin Changes are Highly Dependent on TSH in Low-risk DTC Patients not Treated with Radioiodine.
Matrone A; Faranda A; Latrofa F; Gambale C; Stefani Donati D; Molinaro E; Agate L; Viola D; Piaggi P; Torregrossa L; Basolo F; Elisei R
J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32453405
[TBL] [Abstract][Full Text] [Related]
23. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal.
Elisei R; Schlumberger M; Driedger A; Reiners C; Kloos RT; Sherman SI; Haugen B; Corone C; Molinaro E; Grasso L; Leboulleux S; Rachinsky I; Luster M; Lassmann M; Busaidy NL; Wahl RL; Pacini F; Cho SY; Magner J; Pinchera A; Ladenson PW
J Clin Endocrinol Metab; 2009 Nov; 94(11):4171-9. PubMed ID: 19850694
[TBL] [Abstract][Full Text] [Related]
24. Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients.
Schlumberger M; Hitzel A; Toubert ME; Corone C; Troalen F; Schlageter MH; Claustrat F; Koscielny S; Taieb D; Toubeau M; Bonichon F; Borson-Chazot F; Leenhardt L; Schvartz C; Dejax C; Brenot-Rossi I; Torlontano M; Tenenbaum F; Bardet S; Bussière F; Girard JJ; Morel O; Schneegans O; Schlienger JL; Prost A; So D; Archambeaud F; Ricard M; Benhamou E
J Clin Endocrinol Metab; 2007 Jul; 92(7):2487-95. PubMed ID: 17426102
[TBL] [Abstract][Full Text] [Related]
25. [Hormonal therapy in differentiated carcinoma of the thyroid gland].
Francia G; Davì MV; Petroziello A; Sussi PL
Chir Ital; 1994; 46(4):56-8. PubMed ID: 7882445
[TBL] [Abstract][Full Text] [Related]
26. Does a highly sensitive thyroglobulin (Tg) assay change the clinical management of low-risk patients with thyroid cancer with Tg on T4 < 1 ng/ml determined by traditional assays?
Rosario PW; Purisch S
Clin Endocrinol (Oxf); 2008 Mar; 68(3):338-42. PubMed ID: 17850379
[TBL] [Abstract][Full Text] [Related]
27. The diagnostic use of the rhTSH/thyroglobulin test in differentiated thyroid cancer patients with persistent disease and low thyroglobulin levels.
Pellegriti G; Scollo C; Regalbuto C; Attard M; Marozzi P; Vermiglio F; Violi MA; Cianci M; Vigneri R; Pezzino V; Squatrito S
Clin Endocrinol (Oxf); 2003 May; 58(5):556-61. PubMed ID: 12699436
[TBL] [Abstract][Full Text] [Related]
28. Predictive value of preablation stimulated thyroglobulin and thyroglobulin/thyroid-stimulating hormone ratio in differentiated thyroid cancer.
Lin Y; Li T; Liang J; Li X; Qiu L; Wang S; Chen Y; Kang Z; Li F
Clin Nucl Med; 2011 Dec; 36(12):1102-5. PubMed ID: 22064080
[TBL] [Abstract][Full Text] [Related]
29. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma.
Mazzaferri EL; Robbins RJ; Spencer CA; Braverman LE; Pacini F; Wartofsky L; Haugen BR; Sherman SI; Cooper DS; Braunstein GD; Lee S; Davies TF; Arafah BM; Ladenson PW; Pinchera A
J Clin Endocrinol Metab; 2003 Apr; 88(4):1433-41. PubMed ID: 12679418
[TBL] [Abstract][Full Text] [Related]
30. Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma.
Heemstra KA; Liu YY; Stokkel M; Kievit J; Corssmit E; Pereira AM; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2007 Jan; 66(1):58-64. PubMed ID: 17201802
[TBL] [Abstract][Full Text] [Related]
31. Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole-body scan?
Salvatori M; Perotti G; Rufini V; Maussier ML; Dottorini M
Clin Endocrinol (Oxf); 2004 Dec; 61(6):704-10. PubMed ID: 15579184
[TBL] [Abstract][Full Text] [Related]
32. Unstimulated high sensitive thyroglobulin measurement predicts outcome of differentiated thyroid carcinoma.
Giovanella L; Maffioli M; Ceriani L; De Palma D; Spriano G
Clin Chem Lab Med; 2009; 47(8):1001-4. PubMed ID: 19589104
[TBL] [Abstract][Full Text] [Related]
33. On-levothyroxine measurement of thyroglobulin is not a reliable test for the follow-up of patients at high risk for remnant/recurrent differentiated thyroid carcinoma.
Gholamrezanezhad A; Saghari M; Mirpour S; Beiki D; Tarbiat A; Javan S; Abdollahzadeh J
Endokrynol Pol; 2007; 58(2):100-4. PubMed ID: 17578824
[TBL] [Abstract][Full Text] [Related]
34. [Clinical significance of serum thyroglobulin and antithyroglobulin antibody in differentiated thyroid cancer after thyroid ablation].
Vincze B; Sinkovics I; Keresztes S; Gergye M; Boér A; Remenár E; Péter I; Szentirmay Z; Kremmer T; Kásler M
Magy Onkol; 2004; 48(1):27-34. PubMed ID: 15105893
[TBL] [Abstract][Full Text] [Related]
35. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma.
Lee J; Yun MJ; Nam KH; Chung WY; Soh EY; Park CS
Thyroid; 2010 Feb; 20(2):173-9. PubMed ID: 20151824
[TBL] [Abstract][Full Text] [Related]
36. Serial post-surgical stimulated and unstimulated highly sensitive thyroglobulin measurements in low- and intermediate-risk papillary thyroid carcinoma patients not receiving radioactive iodine.
Kashat L; Orlov S; Orlov D; Assi J; Salari F; Walfish PG
Endocrine; 2016 Nov; 54(2):460-466. PubMed ID: 27189148
[TBL] [Abstract][Full Text] [Related]
37. Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients.
Brassard M; Borget I; Edet-Sanson A; Giraudet AL; Mundler O; Toubeau M; Bonichon F; Borson-Chazot F; Leenhardt L; Schvartz C; Dejax C; Brenot-Rossi I; Toubert ME; Torlontano M; Benhamou E; Schlumberger M;
J Clin Endocrinol Metab; 2011 May; 96(5):1352-9. PubMed ID: 21389143
[TBL] [Abstract][Full Text] [Related]
38. Stimulated thyroglobulin values above 5.6 ng/ml before radioactive iodine ablation treatment following levothyroxine withdrawal is associated with a 2.38-fold risk of relapse in Tg-ab negative subjects with differentiated thyroid cancer.
Mousa U; Yikilmaz AS; Nar A
Clin Transl Oncol; 2017 Aug; 19(8):1028-1034. PubMed ID: 28258491
[TBL] [Abstract][Full Text] [Related]
39. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients.
Baudin E; Do Cao C; Cailleux AF; Leboulleux S; Travagli JP; Schlumberger M
J Clin Endocrinol Metab; 2003 Mar; 88(3):1107-11. PubMed ID: 12629092
[TBL] [Abstract][Full Text] [Related]
40. Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement.
Spencer CA; LoPresti JS; Fatemi S; Nicoloff JT
Thyroid; 1999 May; 9(5):435-41. PubMed ID: 10365673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
